Suppr超能文献

2016-2020 年俄罗斯联邦急性冠脉综合征的血运重建。

Myocardial revascularization in Russian Federation for acute coronary syndrome in 2016-2020.

机构信息

National Medical Research Center of Surgery named after A. Vishnevsky, Moscow, Russia.

National Medical Research Center of Cardiology, Moscow, Russia Institution of the Higher Education "A.I. Yevdokimov Moscow State University of Medicine and Dentistry", Moscow, Russia.

出版信息

Kardiologiia. 2021 Dec 31;61(12):4-15. doi: 10.18087/cardio.2021.12.n1879.

Abstract

Aim    To analyze the number of cases of acute coronary syndrome (ACS) [ST segment elevation myocardial infarction (STEMI), non-ST elevation acute coronary syndrome (nSTEACS)] and results of myocardial revascularization for ACS as a part of the monitoring performed by the Ministry of Health Care of Russia*. This analysis allows, on one hand, providing control of morbidity and mortality of patients with socially significant pathologies and, on the other hand, monitoring the effectivity of treatments to identify and correct their shortcomings. Time-related changes in results of myocardial revascularization performed for ACS patients in the Russian Federation in 2020 were analyzed and compared with the values of 2016-2019 based on data of the Russian Ministry of Health Care monitoring.Material and methods    Yearly absolute, relative, and calculated indices of revascularization for ACS were analyzed and compared based on data of the Russian Ministry of Health Care monitoring in 2016-2020.Results    In the Russian Federation in 2020, the lowest number of hospitalizations for ACS (403, 931) was recorded with an unprecedented ratio of 1 / 1.8 for STEMI/nSTEACS, respectively. In Russia in 2020, the proportion of primary percutaneous coronary interventions (pPCI) for STEMI continued growing; it reached 44% and peaked to the maximum for 2016-2020. At the same time, the thrombolytic therapy (TLT) remained essential in the structure of reperfusion strategies during those years (24.0-27.3 % of all STEMI cases). Total death rate of admitted patients with STEMI in Russia was stable at the level of 13.1-14.6 %. In 2020, there were no significant differences in quality indexes of the treatment for STEMI from the previous period (2016-2019). A yearly relative increase in the number of PCIs for STEACS (from 16 % in 2016 to 30 % in 2020 and from 30% to 46% for high-risk nSTEACS) was observed. In 2020, a significant increase in death rate was observed for nSTEACS as a whole (to 4.1 %) and for individual subgroups (high-risk nSTEACS, to 4.5 %; after PCI for nSTEACS, to 1.8 %; and after PCI for high-risk nSTEACS, to 2.8 %) whereas mean death rate values in these subgroups in 2016-2019 were 2.75 %, 3.45 %, 1.5 %, and 2.3 %, respectively.Conclusion    The analysis of revascularization indexes in ACS patients based on the Ministry of Health Care of Russia monitoring performed in 2016-2020 showed a number of positive trends, including an increase in the total number of revascularization procedures; a decrease in the time from the disease onset to the endovascular treatment; an increase in the availability of stenting for severe ACS; and general stabilization of the mortality. On the other hand, the Russian Federation is considerably behind European countries in several qualitative and quantitative parameters of health care in ACS, such as pPCI availability, symptom-to-balloon time, total mortality of all hospitalized STEMI patients, and revascularization for nSTEACS. Despite the gradual improvement of relative quantitative indexes of myocardial revascularization for ACS, negative changes in the absolute number of myocardial revascularizations for various forms of ACS and a notable increase in the death rate in nSTEACS were observed in 2020, including patients after PCI. There is no doubt that the negative results of myocardial revascularization in Russia in 2020 were due to the effect of the COVID-19 pandemic.* monitoring of measures to reduce the mortality from ischemic heart disease (letters of the Ministry of Health Care of the Russian Federation of 13.03.2015 # 17-6 /10 / 1-177 and of 24.07.2015 # 17-9 / 10 / 2-4128), which includes monthly collection of data on the Federal Research Institute for Health Organization and Informatics portal, the Automated System for Monitoring of Medical Statistics, at http://asmms.mednet.ru.

摘要

目的 分析俄罗斯卫生部保健监测中的急性冠状动脉综合征(ACS)[ST 段抬高心肌梗死(STEMI)、非 ST 段抬高急性冠状动脉综合征(nSTEACS)]病例数和 ACS 血运重建结果,并以此作为监测的一部分。这种分析一方面可以控制具有社会重要性的疾病的发病率和死亡率,另一方面可以监测治疗效果,以发现并纠正其不足之处。 方法 分析 2020 年俄罗斯联邦 ACS 患者血运重建的结果,并与 2016-2019 年的数据进行比较,这些数据来自俄罗斯卫生部保健监测。 结果 在俄罗斯联邦,2020 年记录的 ACS 住院人数(403931 例)为历史最低水平,STEMI/nSTEACS 的比例分别为 1/1.8,前所未有。2020 年,俄罗斯经皮冠状动脉介入治疗(pPCI)在 STEMI 中的比例继续增长,达到 44%,达到 2016-2020 年的最高水平。与此同时,溶栓治疗(TLT)在这些年的再灌注策略结构中仍然是必不可少的(所有 STEMI 病例的 24.0-27.3%)。俄罗斯 STEMI 住院患者的总死亡率保持在 13.1-14.6%的稳定水平。2020 年,STEMI 治疗的质量指标与前一时期(2016-2019 年)没有显著差异。STEACS 的 PCI 数量逐年相对增加(从 2016 年的 16%增加到 2020 年的 30%,高危 nSTEACS 从 30%增加到 46%)。2020 年,nSTEACS 整体死亡率(增加到 4.1%)和个别亚组(高危 nSTEACS,增加到 4.5%;nSTEACS 后 PCI,增加到 1.8%;高危 nSTEACS 后 PCI,增加到 2.8%)均有所增加,而这些亚组在 2016-2019 年的平均死亡率分别为 2.75%、3.45%、1.5%和 2.3%。 结论 基于 2016-2020 年俄罗斯卫生部保健监测的 ACS 患者血运重建指标分析显示出一些积极趋势,包括血运重建手术总数的增加;从发病到血管内治疗的时间缩短;严重 ACS 支架的可用性增加;以及死亡率的普遍稳定。另一方面,俄罗斯在 ACS 医疗保健的几个定性和定量参数方面与欧洲国家相去甚远,例如 pPCI 的可用性、症状至球囊时间、所有 STEMI 住院患者的总死亡率以及 nSTEACS 的血运重建。尽管 ACS 血运重建的相对定量指标逐渐改善,但 2020 年各种形式的 ACS 的血运重建绝对数量以及 nSTEACS 死亡率的显著增加(包括 PCI 后患者)仍存在负面变化。毫无疑问,2020 年俄罗斯 ACS 血运重建的负面结果是由于 COVID-19 大流行的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验